After Hours
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. The stock was recently discussed on Yahoo Finance as it revealed that Takeda Announces U.S. FDA Approval of Supplemental New Drug Application (sNDA) for ICLUSIG® (ponatinib) in Adult Patients with Newly Diagnosed Ph+ ALL.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Stocks Info
The company is listed on the NYSE and operates within the Drug Manufacturers – Specialty & Generic industry segment. The current market capitalization of Takeda Pharmaceutical Co ADR is $45.22B. A total of 1.78 million shares were traded on the day, compared to an average of 1.79M shares.
In the most recent transaction, TAKEDA PHARMACEUTICAL CO LTD sold 3,703,703 shares of TAK for 8.10 per share on Jan 24 ’24. After the transaction, the 10% Owner now owns 3,755,583 company shares.
Dividend
The dividend paying company demonstrates a positive outlook for investors and helps them generate immediate cash. Takeda Pharmaceutical Co ADR pays an annual dividend of $0.63, resulting in a dividend yield of 4.37%, and it has a price to earnings (P/E) ratio of 36.03.
It has been observed that price targets are rarely accurate, but they can exert some influence from time to time, and are often accepted as valuable in the market. In terms of 52-week highs and lows, TAK has a high of $17.15 and a low of $13.19.
As of this writing, TAK has an earnings estimate of $0 per share for the current quarter. EPS was calculated based on a consensus of 0 estimates, with a high estimate of $0 per share and a lower estimate of $0.
Balance Sheet Annually/Quarterly
An equity investor’s investment can be viewed on a balance sheet by looking at what assets and liabilities the company has. Investors can determine the company’s prospects by calculating its financial ratios based on this information. TAK’s latest balance sheet shows that the firm has $875.00B in Cash & Short Term Investments as of fiscal 2022. There were $4.35T in debt and $2.15T in liabilities at the time. Its Book Value Per Share was $15.24, while its Total Shareholder’s Equity was $5.68T.
Analysts Opinion
There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for TAK is Buy with a score of 4.50.
